When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.
disease state indication(s)
Various, case dependent
clinical use
Various, case dependent
methodology/product platform
Refer to individual tests and technologies
specimen type and requirements
Refer to individual tests for the most current specimen type and requirements
turnaround time
Global (TC & PC): 10 days
cpt code(s)
Refer to individual tests for CPT Code(s)
medicare moldx cpt code
Not applicable
regulatory classification
Refer to individual tests
ordering option
Global (TC & PC)
NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 amNeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 amGenoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 amOur lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.
